Overview

Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Antibodies, Monoclonal
Bevacizumab
Nivolumab